This retrospective cohort study assessed whether sex influences the occurrence of apnoea of prematurity (AOP) in preterm infants. The analysis included a cohort of 24,387 preterm infants born between the gestational ages (GA) of 24 0/7 and 33 6/7 weeks that were admitted to tertiary neonatal care units participating in the Canadian Neonatal Network from January 2011 to December 2015. Of those, 13,983 (57%) were diagnosed with AOP. More females were diagnosed with AOP than males, but the difference in the male/female ratio was marginal (P = 0.058). The majority (89%) of infants diagnosed with AOP received caffeine (89% of males; 89% of females). By using the discontinuation of caffeine therapy as a proxy for the resolution of significant AOP, data analysis showed that females born before 33 6/7 weeks of GA stopped caffeine treatment earlier than males whether the caffeine was discontinued before 34 or 37 weeks of GA. Consequently, females had fewer days of caffeine therapy than males, especially infants born between 26 0/7 and 27 6/7 weeks (P < 0.004), 28 0/7 and 29 6/7 weeks (P < 0.03), and 32 0/7 and 33 6/7 weeks of GA (P < 0.04). Similar trends were observed when the corrected GA at discontinuation of caffeine was used. Given that AOP is indicative of an immature respiratory system, our data suggest that the maturation of the respiratory system might occur more rapidly in females than males. We conclude that sex needs to be considered in future studies on AOP.
INTRODUCTION
Apnoea of prematurity (AOP) is a major respiratory disorder that reflects the functional immaturity of the respiratory control system (Darnall, Ariagno, & Kinney, 2006) . As a result, the occurrence of AOP decreases progressively with age (Bairam, 2007; Darnall et al., 2006; Eichenwald & Committee on Fetus and Newborn, American Academy of Pediatrics, 2016; Henderson-Smart, 1981 A widely accepted definition of AOP is the cessation of breathing for >20 s or the cessation of breathing for <20 s accompanied by bradycardia (heart rate <80 beats min −1 ) and/or oxygen desaturation (<80%). Therefore, AOP must be treated, because there is growing evidence to indicate that the recurrent apnoeas, bradycardias and O 2 desaturation resulting from AOP contribute to other morbidities associated with prematurity, including severe retinopathies and neurocognitive disorders (Di Fiore et al., 2010; Di Fiore, Poets, Experimental Physiology. 2018; 103:1403 -1411 wileyonlinelibrary.com/journal/eph Gauda, Martin, & MacFarlane, 2016; Janvier et al., 2004) . To date, administration of methylxanthines, such as caffeine, remains the best pharmacological treatment option for AOP. By stimulation of breathing, methylxanthines reduce the occurrence of apnoeas, thereby attenuating the deleterious consequences resulting from the recurrent O 2 desaturation and bradycardia that are often associated with AOP (Di Fiore et al., 2016) .
Clinical studies evaluating the incidence of AOP and the efficacy of caffeine treatment typically pool data from males and females to improve statistical power, despite evidence indicating that females metabolize caffeine more rapidly than males (Al-Alaiyan et al., 2001 ).
When pooling male and female data, the assumption is that, for any given gestational age (GA), the incidence of AOP and its associated bradycardia and desaturation is similar in both sexes. However, when compared with females, the prevalence of respiratory disorders is higher in preterm male infants, which raises the possibility that being male significantly affects the incidence of AOP. For instance, newborn males have a higher risk for respiratory distress syndrome at birth (Condò et al., 2017) and are less resistant to hypoxaemic/ischaemic injuries (Mage & Donner, 2004) than females. Males also have a higher incidence of sudden infant death syndrome (Kinney & Thach, 2009) and are more likely to show neurodevelopmental impairment that is correlated with the total days in apnoea than females (Janvier et al., 2004) . Furthermore, animal studies show a clear male bias for respiratory instabilities and apnoeas during the neonatal period (Fournier et al., 2013; Kouchi, Uppari, Joseph, & Bairam, 2017) .
To address the importance of sex as a factor in the incidence of AOP and the initiation or discontinuation of caffeine therapy, we conducted a retrospective study using data collected by the Canadian Neonatal Network (CNN). Our objective was to test the hypothesis that the incidence of AOP and the duration of caffeine therapy are greater in males than females. The information collected and compiled in the CNN database included whether the infant had been diagnosed with AOP, and the GA at both the initiation and discontinuation of caffeine.
Given that detailed information about the frequency and severity of AOP was lacking, we used the absence or discontinuation of caffeine treatment as a main outcome and as a proxy for the resolution of significant AOP.
METHODS

Ethical approval
The study was approved as a retrospective review by the research ethics board at the Centre Hospitalier Universitaire de Québec (CHU 
New Findings
• What is the central question of the study?
Is there a sex-based difference in the incidence of apnoea of prematurity and the success or failure of caffeine therapy in preterm infants?
• What is the main finding and its importance?
Our data show that females received fewer days of caffeine treatment than males. This was most noticeable in infants born between 26 0/7 and 27 6/7 weeks of gestational age. These results highlight the importance of considering sex in clinical and basic research investigating the pathophysiology of apnoea of prematurity.
Study design and population
Our retrospective study was performed on a cohort that included all preterm infants admitted to level 3 neonatal intensive care units were the subjects of the study and were divided by GA into five groups:
24 0/7 -25 6/7 , 26 0/7 -27 6/7 , 28 0/7 -29 6/7 , 30 0/7 -31 6/7 and 32 0/7 -33 6/7 weeks of GA. The CNN abstractors noted only the presence or the absence of AOP (yes or no) and the presence or absence of caffeine (yes or no). Hence, the data collected for our study included AOP diagnosis (yes or no), caffeine use (yes or no) and the last day of caffeine treatment.
Variables and data collection
Outcomes
Apnoea of prematurity is a consequence of an immature respiratory control network. However, the concomitant decrease in arterial O 2 saturation with or without bradycardia is the main clinical concern.
The CNN database noted whether the baby had a diagnosis of AOP or not. Hence, to determine whether the incidence of AOP and the necessity to maintain caffeine therapy are influenced by sex, our primary outcome was the percentage of AOP diagnoses in male and female infants for each GA group. Our secondary outcome was the discontinuation of caffeine therapy as a proxy for the resolution of clinical AOP. In this context, the 12,460 infants who received caffeine were analysed by calculating the following: (i) CGA at discontinuation of caffeine treatment; and (ii) percentage of infants in which caffeine was discontinued before 34 or 37 weeks (i.e. before 34 0/7 and 37 0/7 CGA; Rhein et al., 2014) . This approach assumes that the last day of caffeine treatment corresponded to the day significant apnoea resolved, thus providing an indication (albeit indirect) of the maturity of the respiratory control system.
Statistical analysis
Categorical data are presented as numbers and percentages; continuous data are expressed as the mean ± SD, median and quartile 1-quartile 3. Data are also presented according to GA groups.
A 2 test was used to compare categorical variables. The percentage of males and females with AOP were compared using univariate and multivariate logistic regression analysis to calculate male/female odds ratios (ORs) adjusted for maternal and infant variables. To evaluate any difference between males and females at the time of caffeine discontinuation, we used qualitative and quantitative outcomes. Abbreviations: AOP, apnoea of prematurity; BPD, bronchopulmonary dysplasia; GA, gestational age; IVH, intraventricular haemorrhage; PVL, periventricular leukomalacia; and RDS, respiratory distress syndrome.
TA B L E 1 Maternal and infant characteristics and infant outcomes in infants with or without apnoea of prematurity
The Kaplan-Meier analysis was used to compare the probability that male or female infants were receiving caffeine treatment at a specific CGA. Univariate and multivariate Cox regressions were used to evaluate the association between sex and CGA at caffeine treatment discontinuation and to evaluate the possible interaction of GA with this association. Differences were considered statistically significant at P ≤ 0.05.
RESULTS
After application of exclusion criteria, a total of 24,387 preterm infants born between 24 and 34 weeks of GA were included in the final analyses (Figure 1 ). Infants with AOP were significantly more likely to be delivered by caesarean section and to have mothers who received antenatal steroids and MgSO 4 than infants without AOP (Table 1) . They were also born at a significantly earlier GAs and had lower birth weights and Apgar scores at 5 min than infants without AOP. Significantly more infants diagnosed with AOP had respiratory distress syndrome, bronchopulmonary dysplasia, intraventricular haemorrhage or died than infants without AOP (Table 1) .
More females were diagnosed with apnoea of prematurity
Analysis of the 13,983 infants diagnosed with AOP showed that the odds of being diagnosed with AOP were lower in males than females (OR 0.95, P = 0.057), but not significant. After adjusting for confounding factors, including GA, caesarean section, antenatal steroid use, MgSO 4 treatment, respiratory distress syndrome and Apgar score at 5 min < 7, the odds of AOP diagnosis were significantly lower in males than females (adjusted OR 0.94, P = 0.048). Given that AOP is age dependent, we assessed the percentage of males and females diagnosed with AOP in each of the GA groups and found that AOP was 0.11% higher in females than males at 26-27 weeks of GA (P = 0.05), but there was no significant difference at any other GA (Figure 2 ). Note that the modifying effect of GA was tested but not statistically significant.
Shorter duration of caffeine treatment in females
Among the 12,460 infants diagnosed with AOP who received caffeine, the male/female ratio was identical: 89% of males and 89% of females.
The GA at caffeine initiation did not differ between sexes (Table 2) .
However, caffeine treatment was discontinued earlier in females than males; results reported in Table 3a indicate that after adjusting for confounding factors, caffeine discontinuation was less likely in males than females. In this analysis, there was a significant interaction between sex and GA group (P = 0.04). Indeed, the adjusted hazard ratio (male/female) for each GA group showed that males born at 26-27 or 32-33 weeks of GA are significantly less 'at risk' of caffeine discontinuation than females (Table 3b) . Along with sex, GA, caesarean section, respiratory distress syndrome at birth and Apgar score at 5 min < 7 were also associated with prolonged caffeine treatment (Table 3a) .
Females had a lower probability of using caffeine at later CGAs, as
shown by the Kaplan-Meier curves presented in Figure 3 . The sexbased difference was significant for infants born at 26-27 (P < 0.001),
28-30 (P < 0.01) and 32-33 weeks of GA (P < 0.03). However, the difference was not significant for those born at 24-25 and 30-31 weeks of GA. Finally, males were significantly less likely to be off caffeine than females, particularly infants born at 24-25 and 26-27 weeks of GA, regardless of when the caffeine treatment was discontinued (i.e. before 34 or before 37 weeks of CGA; Figure 4a ,b). Abbreviations: AOP, apnoea of prematurity. * Infants diagnosed with AOP. Infants who died while on caffeine therapy were not included in the study.
Gestational age (weeks)
Together, these results indicate that in extremely premature infants the females required less caffeine treatment than males, suggesting that the resolution of significant AOP occurred earlier in females than in males, especially in infants <27 weeks of GA.
DISCUSSION
The main objective of this retrospective study using a large, population-based cohort of premature infants was to determine whether being male or female influences the occurrence of AOP. Given the limitations inherent to the available data, the timing of caffeine therapy discontinuation was used as an indicator of the resolution of clinically significant AOP. Although the prevalence of AOP was higher in females than males born at <27 weeks of GA (Figure 2 ), analyses
showed that the males were treated longer with caffeine. This sexbased difference is most notable for preterm infants aged between 26-29 and 32-33 weeks of GA (Figure 3) . Finally, the longer duration of caffeine treatments for males was consistent whether the caffeine treatment was stopped before 34 or 37 weeks of CGA (Figure 4 ). Given that AOP reflects an immature respiratory system, our observations provide, to the best of our knowledge, the first evidence indicating that the maturation of the respiratory system of preterm infants might be more rapid in females than males. Although the evidence reported here is indirect, it nonetheless warrants further investigations on sex-based differences in the development of respiratory control.
Although we know that the degree of prematurity (Darnall et al., 2006; Henderson-Smart, 1981) and caffeine treatment past 36 weeks of CGA are important predictors of AOP (Dobson et al., 2017;  Eichenwald & Committee on Fetus and Newborn, American Academy of Pediatrics, 2016), the current literature does not provide any explanation for the male bias in infant respiratory disorders, despite TA B L E 3 Association between sex and corrected gestational age (CGA) at discontinuation of caffeine treatment using the Cox proportional hazard model * The hazard ratio of each variable was adjusted for all other variables included in the model (i.e. male hazard ratio was adjusted for gestational age (GA) category, caesarean section, antenatal steroid, MgSO 4 , respiratory distress syndrome and Apgar score at 5 min < 7). P value for the interaction term between sex and GA category: P = 0.04. Hazard ratio and 95% confidence interval (CI) for male versus female by GA category from a multivariate model in (a) plus interaction term between sex and categorized GA (hazard ratio is for male, with female as the reference). F I G U R E 3 Kaplan-Meier curves showing the probably of caffeine usage in males and females by corrected gestational age in infants born between 26 and 27 weeks of gestational age. The table to the right of the curve presents the P values for comparisons of the proportion of females using caffeine with males using caffeine in each gestational age group acknowledging the importance of sex as a factor in the prevalence of several respiratory disorders. For instance, the incidence of sleepdisordered breathing is greater in men than women (Peppard et al., 2013) , the prevalence of asthma is greater in obese boys than girls (Chen, Dong, Lin, & Lee, 2013) , and in newborns, as noted in the Introduction, males are more vulnerable to hypoxaemic/ischaemic injuries or sudden infant death syndrome.
Our understanding of the neuroendocrine mechanisms underlying the male bias in human respiratory disorders is very limited.
Considering that the development of the rodent respiratory control network is very similar to that of human infants (including those born preterm; Bissonnette, 2000; Niane & Bairam, 2011) , recent animal research provides new and highly promising hypotheses. For example, perinatal testosterone secretion in males plays an important role in the sexual differentiation of the brain, a process that can be disrupted by perinatal stress. This information, combined with studies using rat pups, led to the hypothesis that adverse conditions during perinatal development excessively stimulate (or attenuate) testosterone Percentage of infants diagnosed with apnoea of prematurity (AOP) whose caffeine treatment was discontinued before 34 (a) or 37 weeks of corrected gestational age (b). For infants born at <27 weeks of corrected gestational age, more females had discontinued caffeine treatment than males at both 34 and the 37 weeks of corrected gestational age. The inset histograms show the percentage of males and females with discontinued caffeine treatment in the total study population secretion, which compromises development of the male respiratory network such that male pups are predisposed to prolonged and more severe apnoeas (Baldy, Chamberland, Fournier, & Kinkead, 2018; Fournier et al., 2013; Rousseau et al., 2017) . The fact that testosterone levels in sudden infant death syndrome victims are higher than those of control subjects is consistent with this hypothesis (Emery, Krous, Nadeau-Manning, Marck, & Matsumoto, 2005) . In addition, pharmacological investigations revealed that subjecting male rat pups to chronic caffeine treatment during early life (postnatal day 3-12) potentiates the inhibitory action of GABA on basal respiratory activity (Uppari, Joseph, & Bairam, 2016) ; an observation that was less evident in female rats . Subsequent work by the same group showed that the stimulatory effects of acute caffeine administration become more important with age. In 12-dayold pups, the frequency and duration of apnoea is greater in males than females; nonetheless, there is no evidence of sex-based differences in caffeine efficacy to resolve this issue (Kouchi et al., 2017) . Together, our observations highlight the importance of considering sex when studying AOP.
Limitations/interpretations
The large sample size is one strength of our study, but several factors must be kept in mind when considering the conclusions. For example, incomplete information and the consistency of data entry between the different sites were important limitations of this study. For instance, it is widely acknowledged that nearly all infants born before 27 weeks of GA show AOP, but the present study reports that only 68% of infants born between 24 and 25 weeks of GA had a positive AOP diagnosis. Fortunately, the fact that caffeine treatment was initiated at nearly the same age in each GA group and did not differ between males and females is reassuring and helps to validate our study. The reduced proportion of infants with an AOP diagnosis probably reflects a more severe primary diagnosis needing mechanical ventilation, such as respiratory distress syndrome or hyaline membrane disease, a prolonged need for respiratory support, or the high mortality rate in extremely preterm infants. Most extremely preterm infants receive caffeine if they survive to be extubated to non-invasive respiratory support. In some cases, it is possible that caffeine was continued longer for infants with chronic respiratory morbidities; however, the database did not provide that information. The fact that these respiratory disorders are more frequent in boys probably explains the female bias in the extremely preterm population. Of note, our results show that the male to female difference is also significant with preterm infants born at a late gestational age, a group of infants with a low incidence of chronic lung disease (Figure 3) . Furthermore, it is important to note that caffeine treatment protocols (dosage, criteria for pursuit/end of treatment) were not standardized between CNN sites, and it was not always possible to know the exact day of caffeine discontinuation for preterm infants who were discharged home or sent to another hospital with caffeine.
Conclusions
Apnoea of prematurity is a consequence of an immature respiratory control network, and our large cohort study revealed a significant male bias in the proportion of preterm infants that remain on caffeine treatment after 34 and 37 weeks of CGA. This result suggests that the resolution of AOP takes longer in males and, as a corollary, that the development of respiratory control is slower in very preterm male infants. Further work is necessary to test this hypothesis, but the data reported here clearly indicate that sex needs to be considered as a factor in any future investigations regarding AOP and caffeine therapy.
